Study guide

3.6 Diagnostic Testing Strategies

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

3.6 Diagnostic Testing Strategies

Key Takeaways Explain This Topic AI

Diagnostic genetic testing is ordered to explain an existing phenotype or confirmed clinical suspicion; its goal is a molecular or cytogenetic diagnosis that guides management, not population risk stratification.

Choose the test modality from phenotype-driven differentials (single-gene → panel → exome/genome → microarray/karyotype) and escalate when first-line testing is negative or the phenotype is nonspecific.

Cascade (familial) testing uses a known familial pathogenic variant to clarify relatives’ status efficiently; test an affected or informative relative first when possible.

Genotype-first strategies (broad sequencing first) can uncover unexpected diagnoses but increase VUS burden, secondary findings, and pretest counseling complexity.

Board stems reward matching indication, sample, method, and who to test next—not merely naming a technology.

Last updated: August 2026

Diagnostic testing in the Domain 3B frame

Diagnostic genetic testing asks: Does this person have a genetic explanation for their clinical findings? Contrast that with screening (risk stratification in asymptomatic populations), predictive/pre-symptomatic testing (future disease risk in currently healthy people), carrier testing (reproductive risk), somatic tumor profiling (tumor-only alterations), and research testing (protocol-driven discovery). On the CGC exam, Domain 3B items often hinge on recognizing which of these goals the stem is describing before you pick a method or counseling stance.

Diagnostic testing is indicated when there is an existing phenotype , abnormal clinical or laboratory finding, or a confirmed clinical diagnosis that needs molecular confirmation for management, prognosis, or family counseling. A positive diagnostic result can reclassify a syndrome, open targeted therapies or surveillance, and create a family-specific variant for cascade testing.

Who to test first

  • Scenario Preferred first testee Why
  • Proband with clear phenotype The affected individual Highest pretest probability; defines the familial variant

Deceased affected relative, living relative seeking risk Banked DNA/tissue of affected person if available; otherwise closest affected living relative Avoid testing healthy relatives first when the familial variant is unknown

Duo/trio for exome/genome Affected child ± parents Improves de novo vs inherited calls and VUS resolution

Suspected germline cancer predisposition, affected survivor available Affected cancer survivor (or most informative affected relative) Higher yield than testing an unaffected consultand first

Unexplained developmental delay/ID with congenital anomalies Child (often with microarray ± exome pathway per phenotype) Child’s phenotype drives assay choice

Counseling pearl: Testing an unaffected person first when no familial variant is known is usually low-yield and can produce VUS that are hard to interpret. Prefer an informative affected relative whenever feasible.

  • Phenotype-driven vs genotype-first strategies
  • Phenotype-driven (classic diagnostic pathway)

Start with the differential diagnosis built from history, exam, imaging, and family history, then order the narrowest high-yield test :

Single-gene test when one gene explains the presentation (for example, CFTR for classic cystic fibrosis; FBN1 for highly specific Marfan features meeting clinical criteria).

Multigene panel when the differential includes several phenotypically overlapping genes (hereditary hearing loss panels; cardiomyopathy panels; epilepsy panels).

Chromosomal microarray (CMA) for developmental delay/ID, autism with additional features, or multiple congenital anomalies when copy-number variants are high on the differential.

Karyotype / FISH when aneuploidy, large rearrangements, or mosaicism visible at cytogenetic resolution is suspected (for example, Turner syndrome workup, balanced translocation evaluation in recurrent pregnancy loss couples after appropriate indication).

Exome or genome sequencing when the phenotype is genetically heterogeneous, prior targeted testing is negative, or a Mendelian diagnosis is still strongly suspected.

Genotype-first (broad sequencing early)

A genotype-first approach orders exome/genome (sometimes with concurrent CMA) early—especially in critically ill neonates, nonspecific neurodevelopmental phenotypes, or when sequential testing would delay care. Advantages include higher cumulative diagnostic yield and shorter time-to-diagnosis in selected cohorts. Trade-offs you must counsel:

  • Advantage Trade-off
  • Broader capture of unexpected Mendelian diagnoses Higher rate of variants of uncertain significance (VUS)

Can identify atypical presentations of known syndromes Secondary / additional findings (for example, ACMG secondary findings list) need pretest opt-in/opt-out discussion

May end diagnostic odysseys sooner Incidental carrier status, misattributed relationships, and reanalysis burden

Useful when phenotype is evolving or incomplete Insurance and access variability; need for parental samples

Exam trap: Genotype-first is not “always better.” Stems that describe a classic, single-gene phenotype still favor targeted testing first.

Cascade testing

Cascade testing is systematic testing of relatives after a known pathogenic/likely pathogenic familial variant is identified. It is usually site-specific (familial variant analysis), cheaper and clearer than repeating a large panel, and directly answers whether relatives inherited the family’s disease-causing change.

Cascade workflow counselors should know

Confirm the proband’s variant classification and clinical correlation.

Provide written results and a family letter describing the variant, inheritance, and testing options.

Offer testing first to first-degree relatives at highest risk, then extend outward (true cascade).

For autosomal dominant cancer predisposition, a negative familial-variant test generally returns that relative to near-population risk for that gene’s cancer spectrum (with caveats for family history from other causes).

Document who was informed, who declined, and any barriers (geography, insurance, psychosocial readiness).

Duty-to-warn / family communication themes appear more fully in Domain 5, but Domain 3B expects you to know that cascade testing depends on relatives learning about the familial variant—and that genetic counselors facilitate, not coerce, that communication.

Choosing modality by clinical question

  • Clinical question Often appropriate diagnostic approach
  • Suspected aneuploidy or large rearrangement Karyotype ± FISH
  • Multiple congenital anomalies / DD-ID CNV suspicion CMA
  • Classic single-gene disease Single-gene sequencing ± deletion/duplication analysis as indicated
  • Overlapping Mendelian differential Disease-targeted multigene panel
  • Broad undiagnosed Mendelian phenotype Exome/genome ± CNV calling; consider mito coverage if indicated
  • Suspected imprinting disorder Methylation analysis ± MS-MLPA / UPD studies—not “just a panel”
  • Suspected fragile X FMR1 CGG repeat assay—not standard short-read NGS alone

Method–indication mismatch is a high-yield trap: ordering NGS panels when a repeat expansion or methylation test is required will be “negative” for the wrong reason.

Timing, urgency, and parallel testing

Urgent / inpatient neonatal ICU: Broad sequencing ± CMA may run in parallel with metabolic labs; turnaround and sample type (blood, buccal if transfusion issues) matter.

Outpatient diagnostic odyssey: Stepwise testing may be appropriate if insurance requires, phenotype is evolving, or a single high-yield test remains untried.

Prenatal diagnostic testing (CVS/amnio-based) is Domain 3C territory, but the same who/what logic applies: define the familial variant or phenotypic target before choosing the assay.

Integrating pretest counseling into diagnostic strategy

Even when the indication is diagnostic, counsel on:

  • Expected yield for the phenotype and test
  • Possibility of VUS , negative, or unexpected positive results
  • Secondary findings if exome/genome is ordered
  • Implications for relatives and reproductive planning

Limits of a negative test (residual clinical diagnosis; genes not covered; mosaicism; deep intronic / structural variants)

Worked scenario A — phenotype-driven

A 4-year-old with hypotonia, developmental delay, and a clinical suspicion for Prader–Willi syndrome. Best first diagnostic strategy: methylation analysis for 15q11.2-q13 (with follow-up studies to distinguish deletion, UPD, or imprinting defect)—not a random “neurology NGS panel” as the sole first step.

Worked scenario B — cascade

A woman with ovarian cancer has a pathogenic BRCA1 variant. Her unaffected sister seeks testing. Best test: familial BRCA1 variant analysis , not a full hereditary cancer panel as the first step (panel may be considered later if family history suggests additional differentials and the familial variant is negative—or concurrently only when justified).

Worked scenario C — genotype-first

A neonate with unexplained encephalopathy and multiorgan involvement has a nondiagnostic metabolic workup. Rapid exome/genome with parental samples is appropriate; counsel secondary findings and VUS before ordering.

Exam scenarios and traps

Trap — testing the healthy consultand first when an affected relative is available and no familial variant is known.

Trap — equating “negative panel” with “not genetic.” Residual risk remains; consider missed variant types, locus heterogeneity, and non-Mendelian causes.

Trap — using screening language for diagnostic testing. Diagnostic testing does not require Wilson–Jungner population criteria.

Trap — repeating a large panel in every relative instead of cascade testing for a known P/LP variant.

Scenario: Adult with unexplained ataxia—ask whether a repeat-expansion disorder is on the differential before relying on standard NGS alone.

Practice checkpoints

Define diagnostic vs screening vs predictive indications in one sentence each.

State who to test first in cancer, pediatric, and deceased-proband scenarios.

Contrast phenotype-driven escalation with genotype-first trade-offs.

Explain why cascade testing requires a known familial P/LP variant.